Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I suppose Tel Aviv University and Dr. Dorit Arad are both in on Gerald's scam and deception. Right, JPetro? Or is it... "in-vitro testing means nothing, only Phase 3 results and SEC filings can be relied on". LMAO Some here will miss the success story ahead for Todos investors. Too bad.
Onward and upward from here. Picked up shares at the open to hit target of 3.2M shares. I am done buying but was able to lower average price nicely over last couple of weeks. GLTA
CEO on Twitter - 4/2/22 Updated
Video Link:
$TOMDF CEO @G_Commish breaks down IC50 binding affinity in #Ivermectin (50), #Tollovid (<5), #Tollovir (0.8) and #Paxlovid (0.006). Smaller number = tighter binding affinity which stops from doing its job of helping virus replicate & damage immune system.#antiviral #stop3clpro pic.twitter.com/fVJoILwrcf
— Todos Medical (@todosmedical) March 28, 2022
Share Structure Update - 4/1/22
No shares issued since last update on 3/25/22
https://www.otcmarkets.com/stock/TOMDF/security
A diverse approach may be needed to deal with all the damage done by the virus in Long Covid, but it seems clear that Tollovid can address the most critical step... stopping the virus that's causing the damage.
NEWS: Todos Medical Reports Fourth-Quarter and Full-Year 2021 Financial Results and Corporate Updates
New York, NY, and Tel Aviv, ISRAEL, April 01, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today reported financial results for the fourth quarter and full-year ended December 31, 2021 and provided corporate updates.
“2021 was a strong year for Todos Medical and we believe sets the stage for an even stronger year of growth in 2022. We have invested heavily in our newly-acquired Provista Diagnostics lab capabilities and leadership in order to be properly positioned to capture cyclical COVID testing revenue in preparation for the launch of our Videssa breast cancer blood test in early 2023,” said Gerald E. Commissiong, President & CEO of Todos Medical. “We also recently completed the acquisition of the 3CL protease assets of NLC Pharma that positions us as the majority owner of 3CL Pharma Ltd. This dramatically improves our capability to bring to market multiple generations of treatments and diagnostics for coronaviruses, beginning with COVID-19.”
Mr. Commissiong continued, “We had positive results from the Tollovir Phase 2a clinical trial in hospitalized COVID-19 patients, showing superiority to the current standard of care of Remdesivir + dexamethasone, which positions 3CL Pharma to initiate Phase 2b/3 studies in the hospitalized setting. This data allows us to plot our international regulatory authorizations strategy for Tollovir, with an initial focus on an EUA submission in Greece. Tollovid Daily sales were paused to minimize confusion in the market while we gather market research on outcomes from Tollovid Maximum Strength’s use in hopes of pursuing the OTC drug regulatory strategy for acute COVID, Long COVID and pediatric COVID. We are seeing marked increase in interest in 3CL protease inhibitors’ use in Long COVID given recent case reports from physicians about Pfizer’s Paxlovid potential benefit in Long COVID, and the appointment of our first official Tollovid brand ambassador Billy Blanks who supports the use of Tollovid as a the only 3CL protease inhibitor that can be purchased directly by consumers today. Together, our testing and treatment strategy for COVID-19 fits squarely in the ‘Test to Treat’ paradigm President Biden outlined was the future strategy to address the COVID-19 pandemic, and we are now well positioned to drive revenue growth in COVID testing and treatments, as well as in dietary supplements.”
Corporate Highlights:
Completed Acquisition of Key Assets and Intellectual Property from NLC Pharma
Todos Medical recently acquired all the key assets and intellectual property from NLC Pharma. The completion of the acquisition forms a new subsidiary, 3CL Pharma, focused on the development and commercialization of 3CL protease-related products including Tollovir™, Tollovid®, Tollovid Daily™ and TolloTest™ for COVID-19. It positions Todos Medical as the leader of oral antivirals for hospitalized COVID-19 patients to speed time to discharge. Key data from the Tollovir Phase 2 clinical trial showed a reduction of 7.2 days of hospitalization, with 100% of patients meeting the criteria for clinical improvement as measured by NEWS2 compared with 66% in the control group. The Company’s development plans include Tollovir EUA submissions for Worldwide use and preparations for Phase 2b/3 pivotal, and Tollovid initial real-world study to investigate conversion from dietary supplement to over-the-counter drug for long COVID and pediatrics uses.
Announced Positive Primary and Secondary Endpoints Met in NLC-V-01 Phase 2 Clinical Trial of Oral Antiviral 3CL Protease Inhibitor Tollovir™ in the Treatment of Hospitalized COVID-19 Patients Tollovir™ 2022 Double-Blinded Clinical Trial Results
The Phase 2 clinical trial of Tollovir marked a major milestone for Todos Medical and provides the next steps for the Company’s long-term growth plans. Importantly, this has the potential to modify current standards of care. Todos has maintained a strong relationship with NLC and has been highly collaborative and productive providing key discoveries that have the potential to alter the course of the COVID-19 pandemic. Current standard of care (SOC) includes remdesivir and dexamethasone therapy. Phase 2 clinical trial of Tollovir included current standard of care in addition to using Tollovir.
Phase 2 Clinical Trial Results: (Tollovir + SOC vs. SOC alone)
• Mean Reduction of 7.2 days in the hospital
• 100% of Tollovir patients achieved clinical improvement per NEWS2 rating scale versus 66% in placebo arm
• 0% Tollovir death rate while on therapy versus 22% death rate while on therapy in placebo arm
• 73% need for supplement O2 on Tollovir versus 89% need for O2 on placebo
• 3.8 days on supplement O2 on Tollovir versus 5.8 days on supplement O2 on placebo
• Improvement across all biomarkers on Tollovir vs. Placebo
PCR Testing Lab revenue expected to Continue Growth: $5M in 2020 and $12M in 2021
Over the course of the second half of 2021, the Company invested heavily to automate CLIA/CAP laboratoryProvista Diagnosticsin order to be able to perform high quantity PCR testing, primarily for COVID-19, in addition to continuing to distribute PCR testing reagents and supplies to client COVID labs. The fourth quarter of 2021 saw strong growth in the Provista COVID testing business and the Company expects revenues to continue to grow significantly in 2022 as the Company begins to expand its test menu to offer other diagnostics tests for respiratory infections, sexually transmitted infections, uterine tract infections, gastrointestinal, cancer genetics and pharmacogenomics, with its respiratory panel already validated and now being used by physicians. This test menu expansion will allow the Company to service women’s health clinics, skilled nursing homes, cancer diagnostic and treatment centers, OB-GYN physicians and primary care physicians the Company expects to be the primary prescribers of the Videssa breast cancer blood test.
Proprietary testing: Videssa breast cancer test and LymPro Alzheimer’s test
Todos Medical has collected more than 1,000 clinical samples in several clinical trials for breast and other cancers. The latest clinical trial for Todos Medical’s breast cancer test included 59 patients and achieved 93% sensitivity and 87% specificity, as compared to routine mammography screening. The Company intends to launch a clinical study in 2022 to meet the criteria to bring this important test into the market and gain initial reimbursement that will allow the Company to drive sales in 2023.
In addition, the Company is conducting the second stage of an ongoing clinical trial for our LymPro Alzheimer’s blood test at the University of Leipzig in Germany with a readout expected in the first half of 2022. If successful, LymPro, a dynamic functional assay that measures immune response in the blood that mimics ongoing pathology in the brain, will become an important tool to qualify patients who are most likely to benefit from amyloid treatment. LymPro measures the fundamental underlying biology of Alzheimer’s disease and the Company believes it can be identified at the pre-symptomatic phase given that key LymPro markers appear to be stage-independent even at the mild cognitive impairment stage.
Corporate Plans for Uplist to a National Stock Exchange
The Company continues to position itself for a national stock exchange in 2022. The Company expects to file initial public offering documents with the Securities and Exchange Commission needed to complete the transaction in the 2ndquarter of 2022.
Financial Highlights for the Fourth Quarter:
Total revenue in the fourth quarter of 2021 was $4.46 million versus revenues of $3.99 million in 2020. The increase in revenues was primarily driven by a higher rate of COVID testing and Tollovid revenues. The Company expects to focus on driving revenue growth in COVID-19 related diagnostics as well as other testing services through its Provista Diagnostics CLIA/CAP lab business unit. Revenue increased in the fourth quarter at Provista and expected to progressively grow throughout 2022. Revenue per test was up to $250 with average of approximately $80 per test. Total revenue for the full year 2021 was $12.28 million versus revenues of $5.21 million in 2020 which represents a 136% increase. During the first 9 months of 2021 revenue from Covid Testing and Tollovid increased 492% to $7.7 million for versus $1.3 million for 2020. The Company is focused on stable revenue growth in our testing supplies business (Corona Diagnostics) and exponential growth in of lab services testing business (Provista Labs).
Loss from Operations:
The Company recorded an operating loss of $3.59 million in the fourth quarter of 2021 compared to an operating loss of $1.11 million in the fourth quarter of 2020. The increase in net loss was largely a result of unpaid accounts receivable that is being pursued legally. The Company recorded an operating loss of $9.0 million for the full year 2021 compared to an operating loss of $14.3 million for the full year 2020.
Net Income:
The Company recorded a net loss of $18.77 million in the fourth quarter of 2021 compared to a net loss of $4.52 million in the fourth quarter of 2020, largely due to a reduction in expenses. Net loss per share in the fourth quarter of 2021 was $0.12 on 586.8 million weighted average shares outstanding compared to the fourth quarter of 2020 where the Company incurred a net loss of $0.11 per share on 259.2 million weighted average shares outstanding. The Company recorded a net loss of $41.0 million for the full year 2021 compared to a net loss of $29.8 million for the full year 2020.
Select Balance Sheet Items:
The Company had cash of $189,000, trade receivables of $2.8 million and inventory of $1.8 million as of December 31, 2021, compared to cash of $935,000, trade receivables of $378,000, and inventory of $601,000 as of December 31, 2020. Total assets as of December 31, 2021, were $17.4 million compared to $6.0 million as of December 31, 2020. Shareholder deficit was $21.9 million as of December 31, 2021, compared to $11.0 million as of December 31, 2020.
About Todos Medical Ltd.
Founded in Rehovot, Israel with offices in New York City, Todos Medical Ltd. (OTCQB: TOMDF) engineers life-saving diagnostic solutions for the early detection of a variety of cancers. The Company's state-of-the-art and patented Todos Biochemical Infrared Analyses (TBIA) is a proprietary cancer-screening technology using peripheral blood analysis that deploys deep examination into cancer's influence on the immune system, looking for biochemical changes in blood mononuclear cells and plasma. Todos' two internally-developed cancer-screening tests, TMB-1 and TMB-2, have received a CE mark in Europe. Todos recently acquired U.S.-based medical diagnostics company Provista Diagnostics, Inc. to gain rights to its Alpharetta, Georgia-based CLIA/CAP certified lab currently performing PCR COVID testing and Provista's proprietary commercial-stage Videssa®breast cancer blood test.
Todos is also developing blood tests for the early detection of neurodegenerative disorders, such as Alzheimer's disease. The Lymphocyte Proliferation Test (LymPro Test™) is a diagnostic blood test that determines the ability of peripheral blood lymphocytes (PBLs) and monocytes to withstand an exogenous mitogenic stimulation that induces them to enter the cell cycle. It is believed that certain diseases, most notably Alzheimer's disease, are the result of compromised cellular machinery that leads to aberrant cell cycle re-entry by neurons, which then leads to apoptosis. LymPro is unique using peripheral blood lymphocytes as a surrogate for neuronal cell function, suggesting a common relationship between PBLs & neurons in the brain.
Todos has entered into distribution agreements with companies to distribute certain novel coronavirus (COVID-19) test kits. The agreements cover multiple international suppliers of PCR testing kits and related materials and supplies, as well as antibody testing kits from multiple manufacturers after completing validation of said testing kits and supplies in its partner CLIA/CAP certified laboratory in the United States.
Todos has entered into a joint venture with NLC Pharma, Ltd. called 3CL Pharma, Ltd. to pursue the development of oral antiviral therapeutics, dietary supplements and diagnostic tests targeting the 3CL protease. 3CL protease inhibitors target a fundamental reproductive mechanism of coronaviruses.
For more information, please visit https://www.todosmedical.com/.
Forward-looking Statements
Certain statements contained in this press release may constitute forward-looking statements. For example, forward-looking statements are used when discussing our expected clinical development programs and clinical trials. These forward-looking statements are based only on current expectations of management, and are subject to significant risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for product candidates; competition from other biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; and laboratory results that do not translate to equally good results in real settings, all of which could cause the actual results or performance to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Todos Medical does not undertake any obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Todos Medical, please refer to its reports filed from time to time with the U.S. Securities and Exchange Commission.
Todos Corporate Contact:
Daniel Hirsch
CFO
Todos Medical
917-983-4229 x 104
Dan.h@todosmedical.com
Todos Investor Relations Contact:
Eric Ribner
LifeSci Advisors
Email: eric@lifesciadvisors.com
The news release this morning supports your comments on Todos pursuing the FDA approval to market Tollovid as an OTC antiviral for COVID. Seems like things are definitely moving in that direction. Like you, I'm also buying shares. GLTY
NEWS: Todos Medical Reports Case Study of Patient with Long COVID
https://investor.todosmedical.com/news-events/press-releases/detail/183/todos-medical-reports-case-study-of-patient-with-long-covid
New York, NY, and Tel Aviv, ISRAEL, March 31, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its majority-owned subsidiary 3CL Pharma, Ltd. is reporting a case study from a patient with Long COVID who was recommended Tollovid by their physician Dr. John Mabayoje, a family medicine physician based in Richmond, Maryland.
ABSTRACT:
Post-Acute Sequelae of SARS-CoV-2 (PASC), or Long COVID, is a major public health problem. We report a case of breakthrough PASC and its resolution following a course of the 3CL protease inhibitor dietary supplement Tollovid®.
SUMMARIZED CASE REPORT:
A 49-year-old female presented with COVID-19 symptoms of lethargy, persistent positive tests and inability to return to work since she was discharged from the hospital after a short admission with COVID-19. While in the hospital the doctors started her on Standard COVID-19 protocols and discharged her 7 days later with instructions to use home oxygen until she felt better. She weaned herself off of oxygen after 7 days, but she was still unable to return to work due to weakness and a positive COVID-19 nasal PCR test. She suffered from low energy, excessive somnolence, easy fatigability, myalgia, and headaches. A series of blood tests revealed no abnormal findings. However, she persisted in testing positive for COVID-19 on nasal swab specimens. She took a nasopharyngeal swab COVID-19 test every other week for 12 weeks. During this period, she consulted with two physicians who prescribed her acetaminophen and ibuprofen.
After a thorough review of her history, Dr. John Mabayoje concluded that she had long COVID, or what doctors refer to as post-acute sequelae of COVID-19 (PASC), also known as Long Hauler syndrome. Dr. Mabayoje sent her a bottle of commercially available dietary supplement Tollovid that contained 60 capsules and instructed her to take 3 capsules every 6 hours for 5 consecutive days. She responded to the supplement and all of her symptoms were eliminated in 1 week. At the end of the week she tested negative by PCR. She resumed work again after an absence of almost 3 months and has not experienced any COVID or PASC symptoms for 4 months.
About Tollovid®
Tollovid is a dietary supplement product made from natural ingredients that help support and maintain healthy immune function and also has potent 3CL protease inhibition properties based upon in vitro functional assays that show strong inhibition of 3CL protease activity. Tollovid's 3CL protease IC50 binding affinity is at least ten times as strong as Ivermectin’s published 3CL protease IC50 binding affinity. Tollovid binds to the active site (receptor binding domain) of the 3CL protease. Tollovid has a 5-day dosing regimen, with 4 doses of 3 pills taken each day that provides maximum immune support.
About Tollovir®
Tollovir® is a 3CL protease inhibitor and anti-cytokine therapeutic candidate for the treatment of the nidovirus subcategory of coronaviruses that includes SARS-CoV-2, COVID-19, SARS-CoV-1, MERS and 229E. Tollovir is made from all natural ingredients that are qualified to ensure strong inhibition of the 3CL protease in vitro, as well as strong anti-cytokine activity. Tollovir is currently in a Phase 2 clinical trial in Israel for the treatment of patients hospitalized with COVID-19. Tollovir will be developed for the treatment of hospitalized COVID-19 (severe and critical), moderate COVID-19, long-haul COVID and potentially pediatric COVID-19. Todos has licensed rights for Tollovir to T-Cell Protect Hellas S.A. for the Greek market.
About Todos Medical Ltd.
Founded in Rehovot, Israel with offices in New York City, Todos Medical Ltd. (OTCQB: TOMDF) engineers life-saving diagnostic solutions for the early detection of a variety of cancers. The Company's state-of-the-art and patented Todos Biochemical Infrared Analyses (TBIA) is a proprietary cancer-screening technology using peripheral blood analysis that deploys deep examination into cancer's influence on the immune system, looking for biochemical changes in blood mononuclear cells and plasma. Todos’ two internally developed cancer-screening tests, TMB-1 and TMB-2 have received a CE mark in Europe. Todos recently acquired U.S.-based medical diagnostics company Provista Diagnostics, Inc. to gain rights to its Alpharetta, Georgia-based CLIA/CAP certified lab currently performing PCR COVID testing and Provista's proprietary commercial-stage Videssa® breast cancer blood test.
Todos is also developing blood tests for the early detection of neurodegenerative disorders, such as Alzheimer's disease. The Lymphocyte Proliferation Test (LymPro Test™) is a diagnostic blood test that determines the ability of peripheral blood lymphocytes (PBLs) and monocytes to withstand an exogenous mitogenic stimulation that induces them to enter the cell cycle. It is believed that certain diseases, most notably Alzheimer's disease, are the result of compromised cellular machinery that leads to aberrant cell cycle re-entry by neurons, which then leads to apoptosis. LymPro is unique in the use of peripheral blood lymphocytes as a surrogate for neuronal cell function, suggesting a common relationship between PBLs and neurons in the brain.
Todos has entered into distribution agreements with companies to distribute certain novel coronavirus (COVID-19) test kits. The agreements cover multiple international suppliers of PCR testing kits and related materials and supplies, as well as antibody testing kits from multiple manufacturers after completing validation of said testing kits and supplies in its partner CLIA/CAP certified laboratory in the United States. Additionally, Todos has entered into a joint venture with NLC Pharma to pursue the development of diagnostic tests targeting the 3CL protease, as well as 3CL protease inhibitors that target a fundamental reproductive mechanism of coronaviruses.
For more information, please visit https://www.todosmedical.com/.
I also am involved and think I'm somewhat knowledgeable about Todos, and I also don't know why the stock is down. I don't care. It's a buying opportunity for me when others are running scared and selling their shares. I am confident in what I own. Not selling any shares. Buying more. Picked up more this morning, hitting 400K shares in my HSA.
I would hate to be invested here with so little confidence that so many here seem to demonstrate, so fearful they can't stomach 2-3 weeks of no news and fear the worst. That's no way to live life, and no way to invest.
I'm not crazy. I'm buying. If you think this cannot recover you should sell and recover whatever you can. Fear always causes people to lose money. The ones who stay calm and weather the storm will make money.
I'm gonna make a ton of money with Todos. You can always sell now and buy back later if you see it moving up. I'm not playing the fear game.
Past quarterly reports may have been filed late, so you can't rely on the past filing dates. The first quarter 10-Q is due Monday, May 16, not June 30. Todos is a non-accelerated filer.
https://www.broadridge.com/resource/corporate-issuer/edgar-filing-calendar
The deadline for 1st quarter 10-Q is Monday, May 16.
Completed maxing out my HSA for 2022 and picked up more Todos shares this morning. Looking forward to the 10-K today and 10-Q in 46 days.
Maxed my Roth contribution for the year today and bought Todos shares. Will max out my HSA for the year tomorrow and buy more Todos shares. Share price is too good to ignore. I am confident in my DD here.
10-K out soon. Updates on progress soon. Large increase in Covid testing on the horizon with Omicron BA.2 variant raging. Already a new "DeltaCron" variant identified. Covid is not going away. Provista/Todos expected to see continued increase in testing revenues. Marketing campaign for Tollovid working with thousands of views per day, raising product awareness and sales to follow.
Those who need daily or weekly updates to remain confident in their investment should consider moving on or stop watching the daily share price and focus on why invested in the first place. Daily share price watching only for those who not confident in their DD or who shouldn't be investing in penny stocks at all. GLTA
Huge buying opportunity. Buy when others are panic selling. Some assume just because 10-K wasn't delivered early it must be bad news. 3/31 is the filing deadline. Recent marketing videos are getting thousands of views per day. Lots of folks seeing Tollovid for the first time. Continuing increased demand will follow.
Picked up another 77K shares today. I remain confident in what the company is trying to achieve. GLTA
Just picked up another 50K+ shares this morning. Looking forward to that 10-K report.
The CEO hasn't posted much on Twitter over the last couple of weeks. Perhaps one should be asking the question WHY. What has been requiring his attention and focus where he is breaking from his normal pattern? I think we'll find out soon.
I notice the CEO did not engage with Doug09375525 at all on Twitter. That clown went on a multi-day spasm of freaking out and then vanishes completely. Perhaps the clown didn't like having the clown family's criminal record posted for all to see. The internet is not as anonymous as one might think. Must have struck a nerve.
Yes, that was likely me. Picked up shares at 0.023
Looking forward to the 10-K filing.
I picked up more Todos shares this morning on the dip. The 10-K reported this week will shed some light.
It's always darkest before the dawn. The 3CL Pharma closing started the ball rolling for Tollovir. More positive news is coming. I still believe that. There's a reason GC has been quiet on news and on Twitter. GLTA
Share Structure Update - 3/25/22
45,461,783 shares issued since last update on 3/18/22
https://www.otcmarkets.com/stock/TOMDF/security
I'll keep it simple. Where are the SEC FILINGS to verify any of these claims? SEC filings are the ONLY thing one can depend on, in your own words.
I guess it's different standards for MONI, huh?
LMAO
BitGift was tried 4 years ago. It failed. But hey, keep pumping this turd. It has Girl Power and Wall Street Blue Blood backing. LMAO
One would think they would have at least published a marketing survey to show there was demand for a BitGift type product. I guess they missed the previous attempt at BitGift. Probably figured the rabid penny stock crowd would pump anything related to fintech, even if it had been previously tried and failed for lack of interest.
Glad I came to my senses and got out of this turd when I did.
BitGift Announces Full Launch of Their Website
BitGift Announces Full Launch of Their Website to Make Gifting Bitcoin as Simple as a Single Click.
https://www.pr.com/press-release/749516
Todos Medical actually has SEC filings to back up their claims and is a fully reporting company. Great things ahead for this company and I continue to believe shareholders will be greatly rewarded. I hit my 3 million Todos share target on Thursday and added more on Friday. Lots to like here as an investor. Looking forward to the 10-K filing this coming week.
One can continue to trash Todos, who has growing revenue and up-to-date SEC filings, while investing in other companies with no revenue, a lot of hype spread on Twitter, months past stated deadlines, not current in filings, and no evidence in SEC filings of any revenue nor in fulfilling the goals stated. All hype so far. Todos is executing their plan and actually have SEC filings. You know what those are... the only things that matter (in your own words).
Only invest in companies OTC companies with growing revenue and actual SEC filings to back up their "hype". That's the only way to prevent CATASTROPHIC financial losses and insolvency when investing in small OTC companies. Stay away from the pinks until they are listed on OTC and have revenues verified with SEC filings. That's my advice.
Share Structure Update - 3/18/22
16,000,000 shares issued since last update on 3/11/22.
https://www.otcmarkets.com/stock/TOMDF/security
Picked up 68K more shares this morning at the open. Almost at target, should reach it tomorrow.
I want to clarify my last post. I don't think the company intended to deceive anyone in an effort to drive sales. I feel they made a decision about their existing product line and informed customers who had already purchased the product they were discontinuing the Daily product. If they were concerned about driving sales and profits, they wouldn't have offered the discount on both Daily and Max products. I don't believe it was ever an issue with source supply, nor was it an issue with trying to max out the sales for the quarter. I feel it was a marketing effort to support existing customers who, once aware the supply of their product would soon run out, could stock up. I personally stocked up on a 6-month supply of Daily and also ordered one bottle of Max with the discount offered.
I'd rather be notified of the change and allowed to make a decision for myself than have the company remain silent and simply let the product run out, then tell me. That's a way to make customers angry.
Or course, some customers were angry anyway. Some people are always angry about something it seems.
Yes, of course it was a marketing tactic. The company eliminated one product to focus on the other (Max). The "supply chain issues" described in the emails could mean anything. There was never a shortage and that's not what drove this move. Gerald later explained it was a strategic move based on recommendations from those guiding the regulatory approval process for Tollovir.
And according to the emails, there was overwhelming demand for Tollovid Maximum, where there are likely higher margins than for the daily product, so why not focus the attention there. He has also discussed a dual dosing strategy for Max based on whether the user wanted to address an acute issue (testing positive for Covid) or wanted ongoing support.
2-18-22 email:
2-25-22 email:
Here's the Coinbase crypto digital gift card options.
Here's the Moon Equities crypto gift card option. Very appropriate, don't you think, given the wonderful progress being made by the Girl Power running the show here, and the fantastic stock performance all the way down to .01 levels. But all is well. Wink, Wink!!
Really? Alison has a plan? How are those "plans" working out so far?
Aug 25 + 45 days = October 9, 2021. It's now over 5 months later and no Form 10 registration. This auditing team really appears to SUCK, just like the stock performance.
Alison has a plan alright. A crypto gift card with AssClowns on it.
And speaking of crypto gift cards, Coinbase has this already, and they're a $35B company. Why would anyone bother with a crypto card of an unknown company promoted by Wall Street Ass Clowns?
Here's where most people will go who want to gift crypto.
https://www.coinbase.com/gifting
I couldn't agree more. Gerald is the right person to lead Todos Medical to success.
New 90-day extension PR this week, along with PR for closing 3CL Pharma deal. Let the floodgates open for news to follow regarding Tollovir and the emergency use approvals.
Timing is critical to save lives with the new Covid variant driving serious surges in infections around the globe. Many countries will elect to act now and approve Tollovir in light of existing extremely positive data for patient outcomes.
Buying more Todos shares this week.
Nope, MONI will not be kicking ass anytime soon. Not based on tweets by the CEO. It will remain sub-.01 level because the market has figured out this company is nothing but hype and no real substance. BitGift card? Surely no one is thinking that's going to generate enough revenue to make a dent here. Look at other companies who beat MONI to the market with that idea.
Where are the all important SEC filings? In your own words, everything is merely conjecture without the SEC filings. Correct?